Immune response to enzyme replacement therapy in Fabry disease: Impact on clinical outcome?

被引：28

作者：

Hollak, C. E. M. ^{[1
]}

Linthorst, G. E. ^{[1
]}

机构：

[1] Univ Amsterdam, Acad Med Ctr, Dept Internal Med Endocrinol & Metab, NL-1105 AZ Amsterdam, Netherlands

来源：

MOLECULAR GENETICS AND METABOLISM | 2009年 / 96卷 / 01期

关键词：

Fabry disease; Antibody; GL-3; Globotriaosylceramide; Enzyme therapy; Agalsidase; AGALSIDASE-BETA THERAPY; HUMAN ALPHA-GALACTOSIDASE; NEUTRALIZING ANTIBODIES; GAUCHERS-DISEASE; EFFICACY; SAFETY; TRIAL; GLOBOTRIAOSYLCERAMIDE; MANIFESTATIONS; GLUCOSIDASE;

D O I：

10.1016/j.ymgme.2008.10.013

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1 / 3

页数：3

共 26 条

[1] Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II:: Results of a phase I/II clinical trial
Amalfitano, A
Bengur, AR
Morse, RP
Majure, JM
Case, LE
Veerling, DL
Mackey, J
Kishnani, P
Smith, W
McVie-Wylie, A
Sullivan, JA
Hoganson, GE
Phillips, JA
Schaefer, GB
Charrow, J
Ware, RE
Bossen, EH
Chen, YT
[J]. GENETICS IN MEDICINE, 2001, 3 (02) : 132 - 138
[2] Agalsidase-beta therapy for advanced Fabry disease - A randomized trial
Banikazemi, Maryam
Bultas, Jan
Waldek, Stephen
Wilcox, William R.
Whitley, Chester B.
McDonald, Marie
Finkel, Richard
Packman, Seymour
Bichet, Daniel G.
Warnock, David G.
Desnick, Robert J.
[J]. ANNALS OF INTERNAL MEDICINE, 2007, 146 (02) : 77 - 86
[3] REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - MACROPHAGE-TARGETED GLUCOCEREBROSIDASE FOR GAUCHERS-DISEASE
BARTON, NW
BRADY, RO
DAMBROSIA, JM
DIBISCEGLIE, AM
DOPPELT, SH
HILL, SC
MANKIN, HJ
MURRAY, GJ
PARKER, RI
ARGOFF, CE
GREWAL, RP
YU, KT
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (21) : 1464 - 1470
[4] A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry disease
Benichou, Bernard
Goyal, Sunita
Sung, Crystal
Norfleet, Andrea M.
O'Brien, Fanny
[J]. MOLECULAR GENETICS AND METABOLISM, 2009, 96 (01) : 4 - 12
[5] Clinical benefit of enzyme replacement therapy in Fabry disease
Breunig, F
Weidemann, F
Strotmann, J
Knoll, A
Wanner, C
[J]. KIDNEY INTERNATIONAL, 2006, 69 (07) : 1216 - 1221
[6] Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I
Dickson, Patricia
Peinovich, Maryn
McEntee, Michael
Lester, Thomas
Le, Steven
Krieger, Aimee
Manuel, Hayden
Jabagat, Catherine
Passage, Merry
Kakkis, Emil D.
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (08) : 2868 - 2876
[7] Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
Eng, CM
Guffon, N
Wilcox, WR
Germain, DP
Lee, P
Waldek, S
Caplan, L
Linthorst, GE
Desnick, RJ
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) : 9 - 16
[8] Methotrexate reduces antibody responses to recombinant human α-galactosidase A therapy in a mouse model of Fabry disease
Garman, RD
Munroe, K
Richards, SM
[J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2004, 137 (03) : 496 - 502
[9] Sustained, long-term renal stabilization after 54 months of agalsidase β therapy in patients with Fabry disease
Germain, Dominique P.
Waldek, Stephen
Banikazemi, Maryam
Bushinsky, David A.
Charrow, Joel
Desnick, Robert J.
Lee, Philip
Loew, Thomas
Vedder, Anouk C.
Abichandani, Rekha
Wilcox, William R.
Guffon, Nathalie
[J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (05): : 1547 - 1557
[10] INDIVIDUALIZED LOW-DOSE ALGLUCERASE THERAPY FOR TYPE-1 GAUCHERS-DISEASE
HOLLAK, CEM
AERTS, JMFG
GOUDSMIT, R
PHOA, SSKS
EK, M
VANWEELY, S
VONDEMBORNE, AEGK
VANOERS, MHJ
[J]. LANCET, 1995, 345 (8963): : 1474 - 1478

← 1 2 3 →